文献速递乳腺癌妇科肿瘤

前苏联十个新独立国家乳腺癌与宫颈癌分期分布比较:一项基于人群的研究

Comparison of breast cancer and cervical cancer stage distributions in ten newly independent states of the former Soviet Union: a population-based study.
PubMed 文献 · Lancet Oncol · 2021-02-05

该研究收集亚美尼亚、阿塞拜疆、白俄罗斯、格鲁吉亚、哈萨克斯坦、吉尔吉斯斯坦、摩尔多瓦、俄罗斯联邦、乌克兰和乌兹别克斯坦2008-17年乳腺癌和宫颈癌的官方统计数据,按TNM分期和年龄分析。结果显示,2013-17年间多数国家超过50%的乳腺癌病例登记为I-II期,而宫颈癌晚期(III-IV期)比例较高,尤其在摩尔多瓦和亚美尼亚超过50%;宫颈癌I期比例随年龄下降而晚期比例随年龄上升。结论提示乳腺癌早期检测有适度进展,但宫颈癌需转向有组织的HPV疫苗接种和筛查计划。

要点

  • 2013-17年,多数分析国家超过50%的乳腺癌病例登记为I-II期,白俄罗斯、哈萨克斯坦和乌克兰超过75%。
  • 宫颈癌晚期(III-IV期)比例高,摩尔多瓦和亚美尼亚超过50%;I期比例随年龄下降,晚期比例随年龄上升。
  • 乳腺癌分期特异性发病率随时间上升,以I期最明显;宫颈癌分期特异性发病率在2008-17年间总体上升。

核心结论

  • 前苏联新独立国家乳腺癌早期检测有适度进展,但宫颈癌负担高且分期变化不利,需转向有组织的HPV疫苗接种和筛查。

研究设计与样本

  • 基于人群的研究,收集亚美尼亚、阿塞拜疆、白俄罗斯、格鲁吉亚、哈萨克斯坦、吉尔吉斯斯坦、摩尔多瓦、俄罗斯联邦、乌克兰和乌兹别克斯坦2008-17年乳腺癌和宫颈癌发病率官方统计数据。
  • 按TNM分期和年龄分析,使用对数线性回归量化年龄标准化率的时间变化。

主要发现

  • 2013-17年,分析国家中超过50%的乳腺癌病例登记为I-II期,白俄罗斯、哈萨克斯坦和乌克兰超过75%。
  • 乳腺癌I期比例在摩尔多瓦和俄罗斯登记处筛查年龄组(50-69岁)最高,在格鲁吉亚和乌克兰15-49岁组最高。
  • 乳腺癌分期特异性发病率随时间上升,以I期最明显;宫颈癌晚期(III-IV期)比例高,摩尔多瓦和亚美尼亚超过50%。
  • 宫颈癌I期比例在所有国家随年龄下降,晚期比例随年龄上升;宫颈癌分期特异性发病率在2008-17年间总体上升。

临床怎么用

  • 乳腺癌在无钼靶筛查情况下(如白俄罗斯)仍观察到高比例早期病变,可作为快速诊断可达到的基准。
  • 宫颈癌需从机会性筛查转向有组织、基于人群、质量保证的HPV疫苗接种和筛查规划。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Screening for breast cancer and cervical cancer in the newly independent states of the former Soviet Union is largely opportunistic, and countries in the region have among the highest cervical cancer incidence in the WHO European Region. We aimed to compare the stage-specific distributions and changes over time in breast cancer and cervical cancer incidence in the newly independent states of the former Soviet Union. METHODS: We collected breast cancer and cervical cancer incidence data from official statistics from Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Republic of Moldova, Russian Federation, Ukraine, and Uzbekistan for the years 2008-17 by tumour, node, metastasis (TNM) stage, and by age where population-based cancer registry data were available. We used log-linear regression to quantify the changes over time in age-standardised rates. FINDINGS: During the period 2013-17, more than 50% of breast cancer cases across the analysed countries, and more than 75% of breast cancer cases in Belarus, Kazakhstan, and Ukraine, were registered at stages I-II. The proportion of stage I breast cancer cases was highest in the screening age group (50-69 years) compared with other ages in Moldova and the Russian registries, but was highest in those aged 15-49 years in Georgia and Ukraine. Breast cancer stage-specific incidence rates increased over time, most prominently for stage I cancers. For cervical cancer, the proportions of cancers diagnosed at a late stage (stages III and IV) were high, particularly in Moldova and Armenia (>50%). The proportion of stage I cervical cancer cases decreased with age in all countries, whereas the proportions of late stage cancers increased with age. Stage-specific incidence rates of cervical cancer generally increased over the period 2008-17. INTERPRETATION: Our results suggest modest progress in early detection of breast cancer in the newly independent states of the former Soviet Union. The high proportions of early-stage disease in the absence of mammography screening (eg, in Belarus) provide a benchmark for what is achievable with rapid diagnosis. For cervical cancer, there is a need to tackle the high burden and unfavourable stage-specific changes over time in the region. A radical shift in national policies away from opportunistic screening toward organised, population-based, quality-assured human papillomavirus vaccination and screening programmes is urgently needed. FUNDING: Union for International Cancer Control, WHO Regional Office for Europe, and Ministry of Health of Ukraine.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Ryzhov A, Corbex M, Piñeros M, et al. Comparison of breast cancer and cervical cancer stage distributions in ten newly independent states of the former Soviet Union: a population-based study. Lancet Oncol. 2021. PMID: 33556324. doi:10.1016/S1470-2045(20)30674-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。